Author

Ellen Ackerstaff

Memorial Sloan Kettering Cancer CenterORCID 0000-0003-4454-7481Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:imaging· 1 Approach:statistical model· 1

Frequent Co-Authors

Amanda W. LundiD· 1 shared Anthony SantellaiD· 1 shared Ashley SchreieriD· 1 shared C. Chad QuarlesiD· 1 shared Daniel LedbetteriD· 1 shared Deborah R. HealeyiD· 1 shared Eleni Andreopoulou· 1 shared Elizabeth J. ShpalliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Amanda W. LundORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MRI-Trackable Mesenchymal Stem Cells for Oncolytic Therapy: A Clinically Feasible Dual-Labeling Protocol

Harshan Ravi, Deborah R. Healey, Neha Damodar, Ellen Ackerstaff, Joy Gumin, Daniel Ledbetter, Frederick F. Lang, Elizabeth J. Shpall, Mayela Mendt Vilchez, Shian-Jy Wang, C. Chad Quarles

This study evaluates a dual-labeling protocol for mesenchymal stem cells with iron oxide particles and an oncolytic virus, showing preserved cellular function and MRI detectability.

bioRxiv · Oct 20, 2026 · PreprintBioengineering

A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses

Inna S. Serganova, Giorgia Colombo, Francesco Ballesio, Jee Hye Kang, Triantafyllia R. Karakousi, Tullio Esposito, Ellen Ackerstaff, Anthony Santella, Ronald G. Blasberg, Nagavarakishore Pillarsetty, Ashley Schreier, Eleni Andreopoulou, Sandra Demaria, Amanda W. Lund, Pier Federico Gherardini, Roberta Zappasodi

This study shows that reducing tumor glycolysis improves immunotherapy responses by normalizing the tumor microenvironment and enhancing immune cell activity.

bioRxiv · Feb 24, 2026 · PreprintImmunology